Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge. The case ...

Exforge Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure - Exforge offers two of the most prescribed high blood pressure medicines in a convenient ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Exforge HCT contains the active ingredients Amlodipine Besilate, ...

EAST HANOVER, N.J., Aug. 4 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge ...

Novartis has been boosted by data from a new study which shows that its new combination antihypertensive Exforge lowers blood pressure in twice as many patients than those on amlodipine alone.

The FDA has approved Novartis‘ Exforge HCT (amlodipine/valsartan/hydrochlorothiazide) tablets, a combination product containing a calcium channel blocker, an ...

Amlodipine (as besylate) 5 mg, valsartan 160 mg; tabs. Exforge combines two antihypertensive drugs that have complementary mechanisms of action: amlodipine, a calcium (Ca+) channel blocker, and ...